What's Happening?
The Department of Health and Social Care and the Scottish government have announced a shortage of two forms of modified-release propranolol, expected to last until 2026. Alerts issued indicate that propranolol 80mg modified-release capsules will be out
of stock until early March 2026, while 160mg capsules will be unavailable from late November 2025 until mid-to-late January 2026. Propranolol is commonly used for cardiovascular conditions, anxiety, and migraine. Pharmacy teams are advised to switch patients to immediate-release tablets to maintain equivalent daily dosages. Prescribers are asked not to initiate new patients on the affected capsules until the shortage is resolved.
Why It's Important?
The shortage of modified-release propranolol could impact patients relying on these medications for cardiovascular and other conditions. The switch to immediate-release tablets may affect treatment efficacy and patient experience, requiring careful management and monitoring. Healthcare providers must ensure patients are informed about the changes and potential side effects. The shortage highlights the importance of medication stockpiling and supply chain management, prompting concerns about government policy on critical medicines.
Beyond the Headlines
The shortage raises ethical and logistical challenges for healthcare providers, who must balance patient needs with available resources. The situation underscores the need for robust policies on medication stockpiling and supply chain resilience to prevent future shortages. It also highlights the importance of patient education and communication in managing treatment changes effectively.
